|
Lung Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The present study demonstrates significant differences in TCR repertoires and the number of predicted neoantigens between EGFR-mutant and wild-type lung tumors.
|
30582659 |
2019 |
|
Lung Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Using mouse models, we studied the immunological profile of mutant EGFR-driven lung tumors before and after erlotinib treatment.
|
31291990 |
2019 |
|
Lung Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Therefore, we utilized two autochthonous EGFR-driven lung tumor models to investigate dynamic microenvironmental responses to EGFR-TKI treatment.
|
30784054 |
2019 |
|
Lung Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Identifying nonsmall-cell lung tumours bearing the T790M EGFR TKI resistance mutation using PET imaging.
|
31132309 |
2019 |
|
Lung Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Additionally, associations were found for EGFR variations in lung tumors and PIK3CA variations in breast tumors.
|
31100334 |
2019 |
|
Lung Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Lung tumors with EGFRΔ19 alterations harbored a lower tumor mutation burden compared with EGFRL858R lung tumors despite similar smoking history.
|
31086949 |
2019 |
|
Lung Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The overall discordance rate in EGFR mutation between primary lung tumor and paired distant metastases in NSCLC is low, although higher discordance rates were observed in bone metastases compared with CNS and lung/pleural metastases.
|
31216329 |
2019 |
|
Lung Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
An EGFR-Induced <i>Drosophila</i> Lung Tumor Model Identifies Alternative Combination Treatments.
|
31217165 |
2019 |
|
Lung Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
But, additionally, we found that depending on its subcellular localization, IKKα has non-overlapping roles in the activation of other different pathways known for their key implication in lung cancer progression: while cytoplasmic IKKα increases EGFR and NF-κB activities in lung tumor cells, nuclear IKKα causes lung tumor progression through c-Myc, Smad2/3 and Snail activation.
|
30867890 |
2019 |
|
Lung Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Although EGFR is expressed in normal cells, the overexpression of EGFR is detected in many human cancers, such as colon, rectum and lung tumors.
|
30612308 |
2019 |
|
Lung Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors.
|
31689114 |
2019 |
|
Lung Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Author Correction: EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.
|
30250255 |
2018 |
|
Lung Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
We previously demonstrated that wild type and mutant EGFRs repress the expression of the ARF tumor suppressor to promote the survival of lung tumor cells.
|
29959911 |
2018 |
|
Lung Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Epidermal growth factor receptor (EGFR) activation was reported to upregulate programmed death-ligand 1 (PD-L1) expression in lung cancer cells and subsequently contribute to immune escape, indicating its critical role in EGFR-driven lung tumors.
|
30766753 |
2018 |
|
Lung Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Accordingly, EGFR and COX-2/TNF-α activation/induction is expected to play important roles in MGL deficiency-driven lung tumors.
|
29348400 |
2018 |
|
Lung Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Herein we report a rare case presenting as multiple lung adenocarcinomas with four different EGFR gene mutations detected in three lung tumors.
|
29577613 |
2018 |
|
Lung Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Further studies with larger sample size are warranted to clarify the association of EGFR mutation status with the lung tumor response after radiotherapy.
|
29275321 |
2018 |
|
Lung Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
(Theranostics 2018; 8(7):1808-1823. doi:10.7150/thno.23177) it was shown that lung tumors resistant to the EGFR-inhibitor (Erlotinib), reprogram their metabolism and acquire a pro-survival dependency on Phosphoglycerate Dehydrogenase (PHGDH) that can be targeted to eliminate resistant tumors.
|
29569651 |
2018 |
|
Lung Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
These results suggest that targeting EGFR ligands may benefit patients who carry EGFR-mutant lung tumors but will not benefit patients with KRAS-mutant lung tumors.
|
29662194 |
2018 |
|
Lung Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Here, we report that the expression of Sal-like protein 4 (SALL4), was significantly higher in EGFR mutated lung tumors than in non-tumor tissue.
|
29691367 |
2018 |
|
Lung Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Lung tumors were found to harbor PIK3CA (invasive lesions) and a rare in-frame insertion of nucleotides in exon 19 of EGFR (lepidic tumor).
|
30268473 |
2018 |
|
Lung Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
According to both univariate and multivariate Cox regression analyses, the adjusted hazard ratios (aHRs) (95% confidence interval [CI]) derived for thoracic RT for lung tumor after EGFR TKI use and tumor response (group 2) compared with EGFR TKI treatment alone (group 1) was 0.72 (0.60-0.85).
|
29703499 |
2018 |
|
Lung Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
We show that initiation and progression of KRAS-driven lung tumors require input from ERBB family receptor tyrosine kinases (RTKs): Multiple ERBB RTKs are expressed and active from the earliest stages of KRAS-driven lung tumor development, and treatment with a multi-ERBB inhibitor suppresses formation of KRAS<sup>G12D</sup>-driven lung tumors.
|
29925636 |
2018 |
|
Lung Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
In contrast, specific epidermal growth factor receptor (EGFR) inhibitors have been used successfully against lung tumors displaying activating mutations in the kinase domain of EGFR.
|
28376232 |
2017 |
|
Lung Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
We showed that rLZ-8 effectively inhibited lung cancer progression and suppressed EGFR expression of lung tumor lesions in mouse model.
|
28198003 |
2017 |